Lantern Pharma Inc. - Common Stock — Cash Flow (NASDAQ:LTRN) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -5.65 M-10.59 M-12.77 M-14.35 M-17.81 M-15.68 M -15.07 M Cash from investing activities -16.14 K-19.53 M179.27 K-930.21 K3.37 M11.06 M 12.07 M Cash from financing activities 23.66 M63.42 M-2.18 M-500 K66.71 K1.5 M — Free cash flow -5.65 M-10.59 M-12.77 M-14.35 M-17.81 M-15.68 M -15.07 M

News

Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript

Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript

Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-03-30

Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript

FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas

Lantern’s cancer drug LP-184 shows promise in phase 1a trial

Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript

Lantern Pharma Inc. 2025 Q3 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2025-11-15

Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

Disney, Brookfield, Nu Holdings and more set to report earnings Thursday

Lantern Pharma shareholders elect directors and approve stock option repricing

Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints